{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:28Z","timestamp":1793826148935,"version":"4.6.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPIG-2025-01-01313"],"award-info":[{"award-number":["IIRPIG-2025-01-01313"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003511","name":"Indian Institute of Technology Roorkee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbrc.2026.153346","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:11:45Z","timestamp":1769213505000},"page":"153346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Bioengineered chimeric VLPs targeting chikungunya virus and SARS-CoV-2 show high immunogenicity in mice"],"prefix":"10.1016","volume":"805","author":[{"given":"Vedita Anand","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanketkumar","family":"Nehul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Bhutkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Shekhar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manidipa","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4148-1026","authenticated-orcid":false,"given":"Richard J.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravindra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-003X","authenticated-orcid":false,"given":"Shailly","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153346_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-Like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"issue":"1 6","key":"10.1016\/j.bbrc.2026.153346_bib2","first-page":"1","article-title":"Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines","volume":"6","author":"Bahar","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.bbrc.2026.153346_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/vaccines8010139","article-title":"Recent progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.bbrc.2026.153346_bib4","unstructured":"VIMKUNYA | FDA, (n.d.). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vimkunya (accessed March 19, 2025)."},{"issue":"12","key":"10.1016\/j.bbrc.2026.153346_bib5","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env\u2013gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.153346_bib6","article-title":"PRAK-03202: a triple antigen virus-like particle vaccine candidate against SARS CoV-2","volume":"7","author":"Mazumder","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2026.153346_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2026.153346_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 virus-like particles by Mammalian expression System","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.153346_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01884-19","article-title":"Spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic ebola viruses in rhesus macaques","volume":"94","author":"Singh","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib10","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.153346_bib11","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","article-title":"Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature","volume":"36","author":"Boigard","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2026.153346_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-014-0233-3","article-title":"Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties","volume":"14","author":"Liu","year":"2014","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.bbrc.2026.153346_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01181-17","article-title":"An envelope-modified tetravalent Dengue virus-like-particle vaccine has implications for Flavivirus vaccine design","volume":"91","author":"Urakami","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbrc.2026.153346_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat. Med."},{"issue":"0 s1","key":"10.1016\/j.bbrc.2026.153346_bib16","first-page":"1","article-title":"Virus-Like particle-based vaccines for Rift Valley fever virus","volume":"0","author":"ell","year":"2011","journal-title":"J. Bioterrorism Biodefense"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153346_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45461-z","article-title":"Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery","volume":"9","author":"Christiansen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.153346_bib18","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3389\/fmicb.2017.02163","article-title":"The rationale for a preventative HCV virus-like particle (VLP) vaccine","volume":"8","author":"Torresi","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbrc.2026.153346_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2025.110394","article-title":"Transformative approaches in SARS-CoV-2 management: vaccines, therapeutics and future direction","volume":"604","author":"Saha","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2026.153346_bib20","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","article-title":"First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2","volume":"4","author":"Smit","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.bbrc.2026.153346_bib21","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.4103\/2468-8827.330656","article-title":"Enveloped virus-like particles as a platform for vaccine development","volume":"6","author":"Diaz-Mitoma","year":"2021","journal-title":"Int. J. Noncommun. Dis."},{"key":"10.1016\/j.bbrc.2026.153346_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2026.153346_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vetimm.2012.04.026","article-title":"Virus-like particles: the new frontier of vaccines for animal viral infections","volume":"148","author":"Crisci","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153346_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2026.153346_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.153346_bib26","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.153346_bib27","doi-asserted-by":"crossref","unstructured":"M. Brisse, S.M. Vrba, N. Kirk, Y. Liang, H. Ly, Emerging concepts and technologies in vaccine development, (n.d.). https:\/\/doi.org\/10.3389\/fimmu.2020.583077.","DOI":"10.3389\/fimmu.2020.583077"},{"key":"10.1016\/j.bbrc.2026.153346_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"10.1016\/j.bbrc.2026.153346_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bbrc.2026.153346_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbiosc.2013.08.015","article-title":"Evaluation of the stability of enterovirus 71 virus-like particle","volume":"117","author":"Lin","year":"2014","journal-title":"J. Biosci. Bioeng."},{"key":"10.1016\/j.bbrc.2026.153346_bib31","author":"Donaldson"},{"key":"10.1016\/j.bbrc.2026.153346_bib32","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.3390\/ijms23158579","article-title":"Virus-like particles: fundamentals and biomedical applications","volume":"23","author":"Mej\u00eda-M\u00e9ndez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153346_bib33","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2026.153346_bib34","author":"Lei"},{"key":"10.1016\/j.bbrc.2026.153346_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11121828","article-title":"Challenges and opportunities in the process development of chimeric vaccines","volume":"11","author":"Chauhan","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.bbrc.2026.153346_bib36","author":"Bachmann"},{"key":"10.1016\/j.bbrc.2026.153346_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","article-title":"Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice","volume":"140","author":"Wang","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2026.153346_bib38","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1128\/JVI.00449-16","article-title":"Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1\/L2 chimeric virus-like particles","volume":"90","author":"Boxus","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib39","article-title":"Chimeric L2-Based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV)","volume":"12","author":"C","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.153346_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0959-440X(00)00064-6","article-title":"Theoretical studies of viral capsid proteins","volume":"10","author":"Phelps","year":"2000","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2026.153346_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0042-6822(95)80027-1","article-title":"Synthesis and assembly of virus-like particles of human papillomaviruses type 6and type 16 in fission yeast Schizosaccharomyces pombe","volume":"206","author":"Sasagawa","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2026.153346_bib42","author":"Haynes"},{"key":"10.1016\/j.bbrc.2026.153346_bib43","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.1128\/JVI.00361-07","article-title":"Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles","volume":"81","author":"Chen","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104808","article-title":"Alphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection","volume":"179","author":"Fatma","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2026.153346_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(07)70107-X","article-title":"Chikungunya, an epidemic arbovirosis","volume":"7","author":"Pialoux","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbrc.2026.153346_bib46","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.1073\/pnas.1713166114","article-title":"Structural studies of Chikungunya virus maturation","volume":"114","author":"Yap","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.153346_bib47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2022.11.012","article-title":"Surface decorated reporter-tagged chikungunya virus-like particles for clinical diagnostics and identification of virus entry inhibitors","volume":"578","author":"Singh","year":"2023","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2026.153346_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198493","article-title":"Chikungunya virus titration, detection and diagnosis using N-Acetylglucosamine (GlcNAc) specific lectin based virus capture assay","volume":"302","author":"Choudhary","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.bbrc.2026.153346_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2018.04.004","article-title":"Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease","volume":"149","author":"Singh","year":"2018","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrc.2026.153346_bib50","author":"Nehul"},{"key":"10.1016\/j.bbrc.2026.153346_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115572","article-title":"Design, synthesis, antiviral evaluation, and in silico studies of acrylamides targeting nsP2 from Chikungunya virus","volume":"258","author":"de Souza","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.153346_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2025.110551","article-title":"Targeting the host protein G3BP1 for the discovery of novel antiviral inhibitors against Chikungunya virus","volume":"608","author":"Mahajan","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2026.153346_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2023.127176","article-title":"Cellular uptake of metal oxide-based nanocomposites and targeting of chikungunya virus replication protein nsP3","volume":"78","author":"Bhatia","year":"2023","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"ISSUE:ISSUE","key":"10.1016\/j.bbrc.2026.153346_bib54","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/1873-3468.70054","article-title":"Structure-based identification of herbacetin and caffeic acid phenethyl ester as inhibitors of S-adenosylmethionine-dependent viral methyltransferase","volume":"599","author":"Bhutkar","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2026.153346_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110111","article-title":"Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus","volume":"759","author":"Bhutkar","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2026.153346_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/iub.2793","article-title":"Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease","volume":"76","author":"Choudhary","year":"2024","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbrc.2026.153346_bib57","article-title":"Revealing and evaluation of antivirals targeting multiple druggable sites of RdRp complex in SARS-CoV-2","author":"Rani","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.bbrc.2026.153346_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109820","article-title":"Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2","volume":"750","author":"Dhaka","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2026.153346_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150746","article-title":"Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody","volume":"734","author":"Singh","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.153346_bib60","author":"Singh"},{"key":"10.1016\/j.bbrc.2026.153346_bib61","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1080\/07391102.2020.1852968","article-title":"Computational guided identification of novel potent inhibitors of N-terminal domain of nucleocapsid protein of severe acute respiratory syndrome coronavirus 2","volume":"40","author":"Dhankhar","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2026.153346_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01664","article-title":"Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach","volume":"11","author":"Choudhary","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.153346_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2023.105279","article-title":"Bioactives from medicinal herb against bedaquiline resistant tuberculosis: removing the dark clouds from the horizon","volume":"26","author":"Singh","year":"2024","journal-title":"Microb. Infect."},{"key":"10.1016\/j.bbrc.2026.153346_bib64","author":"Tomar"},{"key":"10.1016\/j.bbrc.2026.153346_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.30532","article-title":"Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis","volume":"125","author":"Gupta","year":"2024","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2026.153346_bib66","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1080\/07391102.2022.2141895","article-title":"An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders","volume":"41","author":"Sharma","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2026.153346_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.107969","article-title":"Multifunctional inhibitors of SARS-CoV-2 by MM\/PBSA, essential dynamics, and molecular dynamic investigations","volume":"107","author":"Kumar","year":"2021","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bbrc.2026.153346_bib68","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1080\/07391102.2022.2137699","article-title":"Identification of potential mutational hotspots in serratiopeptidase to address its poor pH tolerance issue","volume":"41","author":"Dhiman","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2026.153346_bib69","article-title":"In-silico analysis of novel mutations identified in Chikungunya virus","volume":"38","author":"Alguridi","year":"2025","journal-title":"Gene. Rep."},{"key":"10.1016\/j.bbrc.2026.153346_bib70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/v17030417","article-title":"Structural virology: the key determinants in development of antiviral therapeutics","volume":"17","author":"Handa","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2026.153346_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138580","article-title":"MDbDMRP: a novel molecular descriptor-based computational model to identify drug-miRNA relationships","volume":"287","author":"Daroch","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrc.2026.153346_bib72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/acsinfecdis.4c00992","article-title":"Repurposing efavirenz, the HIV antiretroviral drug for Chikungunya Virus infection","volume":"11","author":"Nehul","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bbrc.2026.153346_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/febs.70399","article-title":"Deubiquitinase inhibitors: Targeting SARS-CoV-2 papain-like protease with antiviral efficacy in a murine model","author":"Choudhary","year":"2026","journal-title":"FEBS J."},{"key":"10.1016\/j.bbrc.2026.153346_bib74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1473-3099(21)00272-3","article-title":"What chikungunya teaches us about COVID-19","volume":"21","author":"Simon","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbrc.2026.153346_bib75","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.bbrc.2026.153346_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.690621","article-title":"COVID-19 pandemic and vaccines update on challenges and resolutions","volume":"11","author":"Khan","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153346_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.153346_bib78","unstructured":"Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness, (n.d.). https:\/\/www.who.int\/publications\/m\/item\/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness (accessed March 19, 2025)."},{"key":"10.1016\/j.bbrc.2026.153346_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006693","article-title":"An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope","volume":"12","author":"Jin","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153346_bib80","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.153346_bib81","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.3390\/v7122926","article-title":"Fluorescent protein-tagged Sindbis Virus E2 Glycoprotein allows single particle analysis of Virus budding from live cells","volume":"7","author":"Jose","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2026.153346_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2026.153346_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150746","article-title":"Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody","volume":"734","author":"Singh","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153346_bib84","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.153346_bib85","article-title":"Identification of SARS-CoV-2 receptor binding inhibitors by in vitro screening of drug libraries","volume":"26","author":"Ben David","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2026.153346_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150746","article-title":"Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody","volume":"734","author":"Singh","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbrc.2026.153346_bib87","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bbrc.2026.153346_bib88","doi-asserted-by":"crossref","first-page":"8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2026.153346_bib89","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(11)60281-X","article-title":"Chikungunya: a re-emerging virus","volume":"379","author":"Burt","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2026.153346_bib90","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1128\/JVI.00252-20","article-title":"Anti-Chikungunya virus monoclonal antibody that inhibits viral fusion and release","volume":"94","author":"Tumkosit","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.153346_bib92","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.1128\/JVI.00370-12","article-title":"A specific domain of the Chikungunya Virus E2 protein regulates particle Formation in human cells: implications for Alphavirus Vaccine design","volume":"86","author":"Akahata","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2026.153346_bib93","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jchromb.2016.04.025","article-title":"Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP","volume":"1032","author":"Lancaster","year":"2016","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bbrc.2026.153346_bib94","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/bit.26935","article-title":"Process monitoring of virus-like particle reassembly by diafiltration with UV\/Vis spectroscopy and light scattering","volume":"116","author":"R\u00fcdt","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bbrc.2026.153346_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9999","article-title":"Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals","volume":"6","author":"Zhu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.153346_bib96","unstructured":"VIMKUNYA | FDA, (n.d.). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vimkunya (accessed January 2, 2026)."},{"key":"10.1016\/j.bbrc.2026.153346_bib97","unstructured":"PREHEVBRIO | FDA, (n.d.). https:\/\/www.fda.gov\/vaccines-blood-biologics\/prehevbrio (accessed January 2, 2026)."},{"key":"10.1016\/j.bbrc.2026.153346_bib98","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2019.05.064","article-title":"Zika virus-like particles (VLPs): stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform","volume":"37","author":"Alvim","year":"2019","journal-title":"Vaccine"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:49:12Z","timestamp":1774007352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26001105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":98,"alternative-id":["S0006291X26001105"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153346","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioengineered chimeric VLPs targeting chikungunya virus and SARS-CoV-2 show high immunogenicity in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153346"}}